Please login to the form below

Not currently logged in

Health economics teams are making significant use of patient reported outcomes

The measures impact reimbursement and also aid payer communication

The majority of pharma companies in the US, Europe and the Asia-Pacific region use patient reported outcomes (PROs) to supplement their outcomes data, according to a new report.

Health Economics and Outcomes Research: Aligning Clinical and Commercial to Meet Payer Demands and Win Reimbursement by Cutting Edge Information reported widespread prevalence of PRO usage among health economic teams.

The trend was found to be highest among European, Canadian and Australian companies, with 88 per cent of those surveyed claiming to rely on PRO data. In emerging markets 75 per cent of companies use PROs, while 55 per cent of surveyed US companies also used this data.

"For the majority of products, PROs offer a wealth of otherwise unknown data," said Michelle Vitko, senior research analyst at Cutting Edge Information.

"In the face of a shaky global economy and tightening budgets, payers are looking for more outcomes and scientific data to make drug pricing and reimbursement decisions."

Market access teams will continue to rely on cost-utility data and other research models to demonstrate a product's benefits, the report noted, but this is now being supplemented with data gather on quality of life, patient satisfaction, pain relief and absenteeism.

By adding PROs data, health economics teams believe a more comprehensive study has an increased likelihood of reimbursement.

22nd August 2012


Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...